Jaguar Animal Health Inc (NASDAQ:JAGX) has entered into an exclusive evaluation period starting April 3, 2017, with a major multinational animal health pharmaceutical company regarding Equilevia™, the lead product candidate for EGUS.
Jaguar closed a dose determination trial of the target commercial paste preparation of Equilevia™ in Q4 2016. The equine veterinarians who conducted the trial were blinded to the treatment project, and Jaguar was blinded to the report at that time. A full assessment of the trial data with scoring of glandular and squamous ulcers has went through independent, blinded assessment by Dr. Frank Andrews, DVM, MS. The report from the dose determination trial will remain private during the 60-day assessment period.
The third-party assessment Dr. Andrews planned of the trial data involved looking at gastroscopy videos for participating horses and assessing each horse compared to 3 distinct EGUS grading measures – the McAllister scoring system which evaluates the severity and number of ulcers; the EGUS Council scoring system, which is applicable for squamous ulcers, and a latest visual analog scoring plan, relevant for both glandular and squamous ulcers, advanced by Dr. Andrews.
Dr. Andrews reported that this trial demonstrated consistency in the assessment of gastric ulcers by the newly advanced visual analog scoring setup against the published EGUS Council and McAllister grading scales. The visual analog scoring setup could be a vital tool in offering increased precision in gastric ulcers of opposing tissue type, like glandular lesions.
As Jaguar reported in January 2016, topline data from the firm’s proof-of-concept study to assess the effectiveness and safety of Equilevia™ suggest that 78 to 89% of horses cured with Equilevia™ had improvement or resolution of glandular ulcers for 14 days during treatment. The trial assessed a 10 grams of Equilevia™ dose administered orally four times daily and 5 grams of Equilevia™ administered twice daily.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.financialstrend.com